UY30001A1 - Alquilsulfonamida quinolinas - Google Patents

Alquilsulfonamida quinolinas

Info

Publication number
UY30001A1
UY30001A1 UY30001A UY30001A UY30001A1 UY 30001 A1 UY30001 A1 UY 30001A1 UY 30001 A UY30001 A UY 30001A UY 30001 A UY30001 A UY 30001A UY 30001 A1 UY30001 A1 UY 30001A1
Authority
UY
Uruguay
Prior art keywords
alquilsulfonamide
quinolin
methods
compounds
formula
Prior art date
Application number
UY30001A
Other languages
English (en)
Inventor
Yan Li
James Woods
Thomas Simpson
Gerard Koether
James Kang
Cristobal Alhambra
Jeffrey Albert
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38163189&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY30001A1 publication Critical patent/UY30001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de Fórmula I donde R1, A, R2, R3, R4, R5, R8, n, m, q, y R son según se describe en la memoria descriptiva, sales farmacéuticamente aceptables, métodos de fabricación, composiciones farmacéuticas que los contienen y métodos para utilizarlos.
UY30001A 2005-12-12 2006-12-11 Alquilsulfonamida quinolinas UY30001A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74943105P 2005-12-12 2005-12-12
US82101606P 2006-08-01 2006-08-01

Publications (1)

Publication Number Publication Date
UY30001A1 true UY30001A1 (es) 2007-07-31

Family

ID=38163189

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30001A UY30001A1 (es) 2005-12-12 2006-12-11 Alquilsulfonamida quinolinas

Country Status (21)

Country Link
US (3) US7608628B2 (es)
EP (1) EP1968944B1 (es)
JP (1) JP5165581B2 (es)
KR (1) KR20080075867A (es)
AR (1) AR056890A1 (es)
AU (1) AU2006325572B2 (es)
BR (1) BRPI0619746A2 (es)
CA (1) CA2633129A1 (es)
DK (1) DK1968944T3 (es)
EC (1) ECSP088546A (es)
ES (1) ES2571834T3 (es)
HK (1) HK1121759A1 (es)
HU (1) HUE029805T2 (es)
IL (1) IL191628A0 (es)
NO (1) NO20083029L (es)
PL (1) PL1968944T3 (es)
PT (1) PT1968944T (es)
RU (1) RU2421447C2 (es)
TW (2) TW200804288A (es)
UY (1) UY30001A1 (es)
WO (1) WO2007069977A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200804288A (en) * 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
BRPI1008349A2 (pt) * 2009-01-30 2016-02-23 Hoffmann La Roche derivados de piperidina tal como antagonistas de receptor de nk3
CN103619366B (zh) 2011-04-15 2018-02-16 马萨诸塞州大学 外科腔引流和闭合***
CN104168854B (zh) 2012-01-24 2017-02-22 史密夫和内修有限公司 多孔结构及其制造方法
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
GB201315846D0 (en) * 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
GB201503207D0 (en) 2015-02-26 2015-04-15 Univ Edinburgh Female health compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177096A (en) * 1989-10-25 1993-01-05 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles and pharmaceutical methods of use thereof
US5248689A (en) * 1989-11-06 1993-09-28 Smithkline Beecham Corporation Substituted N-(imidazolyl)alkyl alanine derivatives
NZ238688A (en) * 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
FR2719311B1 (fr) 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
PL186075B1 (pl) * 1994-05-27 2003-10-31 Smithkline Beechem Spa N-(-etylobenzylo)-3-hydroksy-2-fenylochinolino-4-karboksyamid oraz kompozycja farmaceutyczna zawierająca ten związek
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
TR199800767T2 (xx) * 1995-10-30 1998-07-21 Smithkline Beecham Corporation Proteaz engelleyicileri.
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
GB9524137D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
IL124522A0 (en) * 1995-11-24 1998-12-06 Smithkline Beecham Spa Quinoline derivatives
GB9524104D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
EP0889888A4 (en) * 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
AR014809A1 (es) 1998-04-03 2001-03-28 Advanced Medicine Inc Compuestos multiligazon, composicion farmaceutica, metodo para prepara dichos compuestos y uso de dichos compuestos para preparar medicamentos
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
IL143137A0 (en) * 1998-11-20 2002-04-21 Smithkline Beecham Spa Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
PT1181288E (pt) * 1999-05-27 2003-12-31 Upjohn Co Oxazolidinonas biciclicas como agentes antibacterianos
US6858630B2 (en) * 1999-12-06 2005-02-22 Smithkline Beecham Corporation Naphthimidazole derivatives and their use as thrombopoietin mimetics
US6248136B1 (en) * 2000-02-03 2001-06-19 Micell Technologies, Inc. Methods for carbon dioxide dry cleaning with integrated distribution
WO2002013825A1 (en) 2000-08-11 2002-02-21 Smithkline Beecham P.L.C. Novel pharmaceutical use of quinnoline derivatives
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
GB0027701D0 (en) * 2000-11-13 2000-12-27 Smithkline Beecham Spa Novel compounds
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
US20040006135A1 (en) * 2002-06-19 2004-01-08 Pfizer Inc. Combination treatment for depression and anxiety
GB0228288D0 (en) 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0228287D0 (en) 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
US7459472B2 (en) 2003-08-08 2008-12-02 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
CA2531796A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
JPWO2005023771A1 (ja) 2003-09-05 2006-11-02 小野薬品工業株式会社 ケモカインレセプターアンタゴニストおよびその医薬用途
US20070244152A1 (en) 2004-03-25 2007-10-18 Lowy Martin T Use of an Nk3 Antagonist for the Treatment of Bipolar Disorders
JP2007536369A (ja) 2004-05-06 2007-12-13 ファイザー・インク プロリン及びモルホリン誘導体の新規化合物
GB0425077D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0509405D0 (en) 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
CN101208304A (zh) 2005-06-23 2008-06-25 阿斯利康(瑞典)有限公司 作为nk3受体调节剂的喹啉3-磺酸酯
US20080200504A1 (en) * 2005-08-11 2008-08-21 Astrazeneca Ab Amide Alkyl Pyridiyl Quinolines as Nk3 Receptor Modulators
CA2618827A1 (en) 2005-08-12 2007-02-22 The Regents Of The University Of California Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
TW200804288A (en) * 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
US20090054445A1 (en) * 2006-01-27 2009-02-26 Astrazeneca Ab Amide Substituted Quinolines
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina

Also Published As

Publication number Publication date
RU2008121761A (ru) 2010-01-20
EP1968944A1 (en) 2008-09-17
TW201018662A (en) 2010-05-16
KR20080075867A (ko) 2008-08-19
DK1968944T3 (en) 2016-08-01
PT1968944T (pt) 2016-07-29
WO2007069977A1 (en) 2007-06-21
AR056890A1 (es) 2007-10-31
RU2421447C2 (ru) 2011-06-20
ES2571834T3 (es) 2016-05-27
US7608628B2 (en) 2009-10-27
BRPI0619746A2 (pt) 2011-10-11
US20080021062A1 (en) 2008-01-24
JP2009519331A (ja) 2009-05-14
EP1968944B1 (en) 2016-04-20
TW200804288A (en) 2008-01-16
AU2006325572B2 (en) 2011-02-24
HK1121759A1 (zh) 2009-04-30
CA2633129A1 (en) 2007-06-21
NO20083029L (no) 2008-07-09
JP5165581B2 (ja) 2013-03-21
PL1968944T3 (pl) 2016-11-30
AU2006325572A1 (en) 2007-06-21
US20080293765A1 (en) 2008-11-27
ECSP088546A (es) 2008-07-30
US20100029717A1 (en) 2010-02-04
US8071621B2 (en) 2011-12-06
HUE029805T2 (en) 2017-03-28
EP1968944A4 (en) 2011-01-12
IL191628A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY31524A1 (es) Nuevos compuestos 010
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
UY30327A1 (es) Nuevos compuestos ii
CR10148A (es) Derivados de las benzamidas y heteroarenos
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
UY29896A1 (es) Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
GT200600518A (es) Derivados de pirimidina
CR9587A (es) Derivados de piridazina
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
ATE459622T1 (de) Tropanverbindungen
UY30206A1 (es) Derivados de diamina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
ECSP088549A (es) Nuevos derivados de pirrol fusionado
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
DOP2010000323A (es) Pirimidin-5-carboxamidas sustituidas 281
CR11826A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
UY30087A1 (es) Piperazinas y piperidinas como potenciadoras de mglur5
ECSP088971A (es) Ligandos 101 de los receptores nicotínicos de acetilcolina
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
ECSP12012338A (es) Triazolopiridinas sustituidas
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120605